Indications
Lymphoma Acalabrutinib is a kinase inhibitor indicated for the treatment of adult patients with:
Mantle cell lymphoma (MCL) who have received at least one prior therapy
This indication is approved under accelerated approval based on overall response rate Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials
Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Dosage And Administration
The recommended dose is 100 mg orally approximately every 12 hours; swallow whole with water and with or without food. Advise patients not to break, open, or chew capsules. Manage toxicities using treatment interruption, dose reduction, or discontinuation. Avoid Acalabrutinib in patients with severe hepatic impairment.
Side Effects
Most common adverse reactions (incidence ≥30%) were: anemia, neutropenia, upper respiratory tract infection, thrombocytopenia, headache, diarrhea, and musculoskeletal pain.
Precautions And Warnings
Serious and Opportunistic Infections: Monitor for signs and symptoms of infection and treat promptly
Hemorrhage: Monitor for bleeding and manage appropriately
Cytopenias: Monitor complete blood counts regularly
Second Primary Malignancies: Other malignancies have occurred, including skin cancers and other solid tumors. Advise patients to use sun protection
Atrial Fibrillation and Flutter: Monitor for symptoms of arrhythmias and manage
Pregnancy And Lactation
Based on findings in animals, Acalabrutinib may cause fetal harm and dystocia when administered to a pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. No data are available regarding the presence of Acalabrutinib or its active metabolite in human milk, its effects on the breastfed child, or on milk production.